Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms

被引:50
作者
Field, TR
White, A
Elborn, JS
Tunney, MM
机构
[1] Queens Univ Belfast, Ctr Med Biol, Sch Pharm, Clin & Practice Res Grp, Belfast BT9 7BL, Antrim, North Ireland
[2] Queens Univ Belfast, Inflammat Res Ctr, Resp Med Res Grp, Belfast BT12 6BA, Antrim, North Ireland
关键词
D O I
10.1007/s10096-005-0031-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pseudomonas aeruginosa, the predominant causative pathogen of chronic lung infection in patients with cystic fibrosis, may grow under anaerobic conditions as biofilms in the lungs of cystic fibrosis patients. To determine if growth under anaerobic conditions affects the antimicrobial susceptibility of P. aeruginosa, the susceptibility of clinical isolates of P. aeruginosa grown planktonically and as biofilms to a range of antibiotics was determined. Growth under anaerobic conditions did not reduce the ability of ceftazidime, meropenem, aztreonam, piperacillin, or piperacillin/tazobactam to inhibit planktonic growth, with MIC50 values for these antibiotics remaining unchanged or decreasing. However, tobramycin was less effective at inhibiting planktonic bacterial growth under anaerobic conditions, with the MIC50 of tobramycin increasing twofold. Growth under anaerobic conditions also decreased the bactericidal activity of tobramycin, with the MBC50 of tobramycin increasing fourfold. The killing kinetics of tobramycin was also examined under aerobic and anaerobic conditions for selected isolates. When isolates 6A and 12A were grown aerobically, concentration-dependent decreases in total viable count were apparent with tobramycin. In contrast, when these isolates were grown anaerobically, tobramycin at the same concentrations did not decrease the total viable count. When isolates were grown as biofilms under both aerobic and anaerobic conditions, isolate- and concentration-dependent differences in killing of the biofilms by tobramycin were apparent. However, tobramycin at concentrations up to 128 mg/l was unable to eradicate biofilms of any of the isolates tested, whether biofilms were grown aerobically or anaerobically. These results show that oxygen limitation may reduce, in a strain-dependent manner, the susceptibility to tobramycin of P. aeruginosa grown planktonically and as biofilms.
引用
收藏
页码:677 / 687
页数:11
相关论文
共 29 条
[1]   Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia [J].
Aaron, SD ;
Ferris, W ;
Henry, DA ;
Speert, DP ;
MacDonald, NE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1206-1212
[2]   Determination of minimum inhibitory concentrations [J].
Andrews, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :5-16
[3]   Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms [J].
Borriello, G ;
Werner, E ;
Roe, F ;
Kim, AM ;
Ehrlich, GD ;
Stewart, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2659-2664
[4]   An overview of the pathogenesis of cystic fibrosis lung disease [J].
Boucher, RC .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (11) :1359-1371
[5]   A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms [J].
Brooun, A ;
Liu, SH ;
Lewis, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :640-646
[6]   The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms [J].
Ceri, H ;
Olson, ME ;
Stremick, C ;
Read, RR ;
Morck, D ;
Buret, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) :1771-1776
[7]   Bacterial biofilms: A common cause of persistent infections [J].
Costerton, JW ;
Stewart, PS ;
Greenberg, EP .
SCIENCE, 1999, 284 (5418) :1318-1322
[8]   TOLERANCE OF PSEUDOMONAS-AERUGINOSA TO KILLING BY CIPROFLOXACIN, GENTAMICIN AND IMIPENEM INVITRO AND INVIVO [J].
DAVEY, P ;
BARZA, M ;
STUART, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 21 (04) :395-404
[9]   Incidence, population, and survival of cystic fibrosis in the UK, 1968-95 [J].
Dodge, JA ;
Morison, S ;
Lewis, PA ;
Coles, EC ;
Geddes, D ;
Russell, G ;
Littlewood, JM ;
Scott, MT .
ARCHIVES OF DISEASE IN CHILDHOOD, 1997, 77 (06) :493-496
[10]   Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis [J].
Geller, DE ;
Pitlick, WH ;
Nardella, PA ;
Tracewell, WG ;
Ramsey, BW .
CHEST, 2002, 122 (01) :219-226